Group 1 - The company, 信铭生命科技 (00474), reported a revenue of HKD 29 million for the six months ending September 30, 2025, representing a year-on-year increase of 26.09% [1] - The profit attributable to the company's owners was HKD 386 million, marking a turnaround from a loss to profit year-on-year [1] - The basic earnings per share were HKD 0.0527 [1]

Group 1 - The core viewpoint of the article is that 信铭生命科技 (00474.HK) reported a significant increase in revenue and a turnaround in profit for the six months ending September 30, 2025, compared to the same period last year [1] - The total revenue for the period was approximately HKD 29 million, up from approximately HKD 23 million in the same period last year, primarily due to a reduction in rent concessions offered to tenants [1] - The company generated a profit of approximately HKD 386 million from continuing operations, a significant improvement from a loss of HKD 114 million in the same period last year, mainly due to the sale of a subsidiary, 昊天国际建设投资 [1]

Financial Performance - For the six months ended September 30, 2025, the company reported revenue of HKD 29 million, an increase of 26.1% compared to HKD 23 million for the same period in 2024[3]. - The company achieved a profit from continuing operations of HKD 386 million, compared to a loss of HKD 114 million in the previous year, indicating a significant turnaround[4]. - Total comprehensive income for the period was HKD 313 million, a recovery from a loss of HKD 173 million in the same period last year[4]. - The basic earnings per share from continuing operations was HKD 5.27, compared to a loss per share of HKD 1.59 in the previous year[5]. - The group’s total income for the six months ended September 30, 2025, was HKD 465 million, compared to a loss of HKD 3 million in the same period last year[19]. - Basic and diluted earnings per share for the period were HKD 5.27, compared to a loss of HKD (1.91) in the previous year[27]. Expenses and Costs - The company reported administrative expenses of HKD 55 million, which increased from HKD 23 million in the previous year, reflecting higher operational costs[3]. - The financing costs decreased to HKD 41 million from HKD 57 million, showing improved financial management[3]. - The group reported other income of HKD 5 million for the six months ended September 30, 2025, compared to HKD 8 million in the previous year, indicating a decrease of 37.5%[19]. - The group incurred interest expenses of HKD 41 million for the six months ended September 30, 2025, down from HKD 57 million in the same period last year, reflecting a reduction of approximately 28.1%[20]. - Administrative expenses increased to approximately HKD 55 million from HKD 23 million in the previous year, largely due to legal and professional fees related to refinancing[41]. Assets and Liabilities - As of September 30, 2025, total assets amounted to HKD 1,722 million, a decrease from HKD 3,243 million as of March 31, 2025[6]. - Total liabilities were HKD 1,352 million, compared to HKD 2,499 million previously[7]. - Current liabilities totaled HKD 229 million, a significant reduction from HKD 1,906 million[7]. - The company's net assets decreased to HKD 370 million from HKD 744 million[7]. - The total equity attributable to owners of the company was HKD 370 million, down from HKD 744 million[7]. - As of September 30, 2025, the group had current assets of approximately HKD 453 million and current liabilities of approximately HKD 229 million[44]. Market Strategy and Operations - The company plans to expand its market presence and invest in new technologies to drive future growth[2]. - The company is focusing on enhancing its product offerings and exploring potential mergers and acquisitions to strengthen its market position[2]. - The company completed the sale of its subsidiary, resulting in a fundamental change in its business model and strategy, now focusing on property leasing[34]. - The core business is centered around high-quality commercial properties in central London, which are leased to reputable international companies[35]. - The company is optimistic about the UK property market recovery and plans to upgrade properties to enhance tenant experience and market value[60]. - Most tenants have expressed willingness to renew leases at potentially higher rental levels, ensuring stable long-term revenue sources[61]. Shareholder and Governance - The company did not recommend the payment of an interim dividend for the six months ended May 12, 2025, and September 30, 2024[25]. - The company did not declare an interim dividend for the period, consistent with the previous year[50]. - The board of directors includes two executive directors, one non-executive director, and three independent non-executive directors[69]. - The company has adhered to corporate governance principles and standards throughout the reporting period[62]. Financial Reporting and Compliance - The financial statements are unaudited and presented in Hong Kong dollars (HKD)[10]. - The group did not apply any new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective, and is currently assessing their potential impact[12]. - The group’s financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and the relevant disclosure requirements of the Listing Rules[12]. - The mid-term performance announcement will be published on the Hong Kong Stock Exchange website and the company's website[68]. - The mid-term report will be sent to shareholders and published on the Hong Kong Stock Exchange and the company's website at the appropriate time[68]. Employee and Operational Changes - The company had 41 employees as of September 30, 2025, a decrease from 146 employees as of March 31, 2025[53].

Core Insights - The company expects to achieve a profit of approximately HKD 380 million for the six-month period ending September 30, 2025, compared to a loss of approximately HKD 195 million in the same period of 2024 [1] Group 1 - The increase in profit is primarily due to gains from the sale of a subsidiary during the reporting period [1]

Core Insights - The company, 信铭生命科技 (00474.HK), expects to report a profit of approximately HKD 380 million for the six months ending September 30, 2025, compared to a loss of about HKD 195 million in the same period of 2024 [1] Financial Performance - The anticipated profit increase is primarily attributed to the gain from the sale of a subsidiary during the reporting period [1]

Core Viewpoint - The company, 信铭生命科技 (00474), anticipates a profit of approximately HKD 380 million for the six-month period ending September 30, 2025, compared to a loss of about HKD 195 million in the same period of 2024. The increase in profit is primarily attributed to gains from the sale of a subsidiary during the reporting period [1]. Summary by Category - **Financial Performance** - Expected profit of approximately HKD 380 million for the six months ending September 30, 2025 [1] - Loss of about HKD 195 million in the same period of 2024 [1] - **Key Drivers** - Profit increase mainly due to gains from the sale of a subsidiary [1]

Aceso Life Science Group Limited 信銘生命科技集團有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00474） 正面盈利預告 本 公 佈 乃 由 信 銘 生 命 科 技 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司， 統 稱「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則 第13.09條 及 香港法例第571章《證 券 及 期 貨 條 例》第XIVA部 項 下 之 內 幕 消 息 條 文 作 出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公司股東及潛在投資者於買賣本公司股份或其他證券時務請審慎行事。 承董事會命 信銘生命科技集團有限公司 執行董事 歐志亮 香 港，二 零 二 五 年 十 一 月 二 十 五 日 於 本 公 告 日 期，董 事 會 成 員 包 括 兩 ...

Core Viewpoint - The company, 信铭生命科技 (Ximing Life Science Technology), is set to hold a board meeting on November 28, 2025, to approve its unaudited interim results for the six months ending September 30, 2025, and to consider the distribution of an interim dividend if applicable [1] Summary by Categories - **Board Meeting Details** - The board meeting will take place at 11:00 AM on November 28, 2025, at the 瑞安中心 (Rui'an Center) in Wan Chai, Hong Kong [1] - **Financial Performance Review** - The meeting will include the approval of the company's unaudited interim results for the six months ending September 30, 2025 [1] - **Dividend Consideration** - The board will also consider the distribution of an interim dividend, subject to availability [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 承董事會命 信銘生命科技集團有限公司 公司秘書 蕭鎮邦 香 港，二 零 二 五 年 十 一 月 十 四 日 Aceso Life Science Group Limited 信銘生命科技集團有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00474） 董事會會議通告 信 銘 生 命 科 技 集 團 有 限 公 司（「本公司」）董 事 會（「董事會」）欣 然 宣 佈，本 公 司 之 董 事 會 會 議 將 於 二 零 二 五 年 十 一 月 二 十 八 日（星 期 五）上 午 十 一 時正在香港灣仔港灣道6-8號瑞安中心25樓2501–2509室 舉 行，以（其 中 包 括） 批准本公司及其附屬公司截至二零二五年九月三十日止六個月之未經 審 核 中 期 業 績 及 其 刊 發，以 及 考 慮 派 發 ...

Group 1 - Hong Kong Stock Exchange data shows that on November 4, shareholders of Sinomax Technology (00474) transferred shares from Shanghai Commercial Bank to Haotian International Securities, with a transfer market value of 90.0295 million HKD, accounting for 11.96% [1] - On October 28, Glory Century Limited increased its stake in Sinomax Technology by acquiring 48 million shares at a price of 0.1046 HKD per share, totaling 5.0208 million HKD. After the increase, the total number of shares held is approximately 403 million, representing a new holding percentage of 5.46% [1]